Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 in advanced HCC and cirrhosis
NCT02151864Phase 1Completed
- Start
- Jul 2014
- Primary completion
- Dec 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonidegib in hepatocellular carcinoma (HCC) and Liver cirrhosis (LC). Primary endpoint: Rate of dose limiting toxicities at 42 days. Started Jul 2014; status: completed.
02
Drugs
sonidegib
03
Conditions
hepatocellular carcinoma (HCC)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02151864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151864.